Adverum Biotechnologies, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Adverum Biotechnologies' 10-K filing reveals substantial doubt about its ability to continue as a going concern due to recurring losses, a material weakness in internal controls, and the need for additional funding.
Adverum Biotechnologies' 2023 annual report details progress in its gene therapy programs, particularly for wet AMD, and outlines financial strategies for continued development.